Patents by Inventor Naoki Ashizawa
Naoki Ashizawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10689408Abstract: It is intended to provide a novel bisphosphonic acid compound or a salt thereof which shows a remarkable inhibitory effect on ectopic calcification, and a pharmaceutical composition comprising the same. The present invention provides a bisphosphonic acid compound represented by the following formula (1) or a pharmaceutically acceptable salt thereof: wherein represents a single bond or a double bond; A represents a saturated cyclic hydrocarbon or a saturated heterocyclic ring comprising a sulfur atom or an oxygen atom; and R1 and R2 each independently represent an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, an aryloxy group, a haloalkoxy group, a haloalkyl group, a halogen atom or a hydrogen atom.Type: GrantFiled: January 27, 2017Date of Patent: June 23, 2020Assignee: FUJIYAKUHIN CO., LTD.Inventors: Seiichi Kobashi, Yoshinobu Aoyagi, Hiroshige Kato, Ryuko Tokuyama, Naoki Ashizawa, Koichi Ishida, Koji Matsumoto
-
Publication number: 20190002482Abstract: It is intended to provide a novel bisphosphonic acid compound or a salt thereof which shows a remarkable inhibitory effect on ectopic calcification, and a pharmaceutical composition comprising the same. The present invention provides a bisphosphonic acid compound represented by the following formula (1) or a pharmaceutically acceptable salt thereof: wherein represents a single bond or a double bond; A represents a saturated cyclic hydrocarbon or a saturated heterocyclic ring comprising a sulfur atom or an oxygen atom; and R1 and R2 each independently represent an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, an aryloxy group, a haloalkoxy group, a haloalkyl group, a halogen atom or a hydrogen atom.Type: ApplicationFiled: January 27, 2017Publication date: January 3, 2019Applicant: FUJIYAKUHIN CO., LTD.Inventors: Seiichi KOBASHI, Yoshinobu AOYAGI, Hiroshige KATO, Ryuko TOKUYAMA, Naoki ASHIZAWA, Koichi ISHIDA, Koji MATSUMOTO
-
Patent number: 8367843Abstract: Disclosed are a novel compound and a pharmaceutical product, each having a remarkable uricosuric effect. Specifically disclosed are: a novel phenol derivative represented by general formula (1) that is shown in FIG. 1; a pharmaceutically acceptable salt thereof; a hydrate of the derivative or the salt; and a solvate of the derivative or the salt. (In the formula, R1 and R2 may be the same or different and each represents a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a lower alkoxy group, a haloalkyl group, a haloalkoxy group, an alkylsulfanyl group, an alkylsulfinyl group, an alkylsulfonyl group, a lower alkyl-substituted carbamoyl group, a saturated nitrogen-containing heterocyclic N-carbonyl group, a halogen atom, a cyano group or a hydrogen atom; R3 represents a lower alkyl group, a haloalkyl group, a halogen atom, a hydroxy group or a hydrogen atom; and X represents a sulfur atom, an —S(?O)— group or an —S(?O)2— group.Type: GrantFiled: September 29, 2010Date of Patent: February 5, 2013Assignee: Fuji Yakuhin Co., Ltd.Inventors: Seiichi Kobashi, Junichiro Uda, Sachiho Miyata, Tsutomu Inoue, Naoki Ashizawa, Koji Matsumoto, Tetsuya Taniguchi, Takashi Iwanaga, Osamu Nagata
-
Publication number: 20120184587Abstract: Disclosed are a novel compound and a pharmaceutical product, each having a remarkable uricosuric effect. Specifically disclosed are: a novel phenol derivative represented by general formula (1) that is shown in FIG. 1; a pharmaceutically acceptable salt thereof; a hydrate of the derivative or the salt; and a solvate of the derivative or the salt. (In the formula, R1 and R2 may be the same or different and each represents a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a lower alkoxy group, a haloalkyl group, a haloalkoxy group, an alkylsulfanyl group, an alkylsulfinyl group, an alkylsulfonyl group, a lower alkyl-substituted carbamoyl group, a saturated nitrogen-containing heterocyclic N-carbonyl group, a halogen atom, a cyano group or a hydrogen atom; R3 represents a lower alkyl group, a haloalkyl group, a halogen atom, a hydroxy group or a hydrogen atom; and X represents a sulfur atom, an —S(?O)— group or an —S(?O)2— group.Type: ApplicationFiled: September 29, 2010Publication date: July 19, 2012Inventors: Seiichi Kobashi, Junichiro Uda, Sachiho Miyata, Tsutomu Inoue, Naoki Ashizawa, Koji Matsumoto, Tetsuya Taniguchi, Takashi Iwanaga, Osamu Nagata
-
Patent number: 7074816Abstract: A novel 1,2,4-triazole compound which is useful as a therapeutic agent for hyperuricemia and gout due to hyperuricemia is provided. A compound is represented by the following general formula (1): wherein R2 represents an unsubstituted or substituted pyridyl group, R1 represents a similar pyridyl group, a pyridine-N-oxide group corresponding to these pyridyl groups, or a phenyl group, and R3 represents hydrogen or a lower alkyl group substituted with pivaloyloxy group and R3 bonds to a nitrogen atom in the ring. A process for production of a compound by reacting a nitrile and a hydrazide, and a therapeutic agent, particularly a xanthine oxidase inhibitor are also provided.Type: GrantFiled: December 3, 2002Date of Patent: July 11, 2006Assignee: Fuji Yakuhin Co., Ltd.Inventors: Hiroshi Nakamura, Soichi Kaneda, Takahiro Sato, Naoki Ashizawa, Koji Matsumoto, Takashi Iwanaga, Tsutomu Inoue
-
Publication number: 20050004175Abstract: A novel 1,2,4-triazole compound which is useful as a therapeutic agent for hyperuricemia and gout due to hyperuricemia is provided. A compound is represented by the following general formula (1): wherein R2 represents an unsubstituted or substituted pyridyl group, R1 represents a similar pyridyl group, a pyridine-N-oxide group corresponding to these pyridyl groups, or a phenyl group, and R3 represents hydrogen or a lower alkyl group substituted with pivaloyloxy group and R3 bonds to a nitrogen atom in the ring. A process for production of a compound by reacting a nitrile and a hydrazide, and a therapeutic agent, particularly a xanthine oxidase inhibitor are also provided.Type: ApplicationFiled: December 3, 2002Publication date: January 6, 2005Inventors: Hiroshi Nakamura, Soichi Kaneda, Takahiro Sato, Naoki Ashizawa, Koji Matsumoto, Takashi Iwanaga, Tsutomu Inoue
-
Patent number: 6136831Abstract: The purpose is to provide anti-inflammatory agents which have potent pharmacological actions and exert a selective inhibitory activity on COX-2, thereby being expected to reduce adverse effects such as disorders in gastric mucosa. The present invention encompasses a compound of the formula (1): wherein R.sup.1 is hydrogen or halogen, R.sup.2 and R.sup.3 are each independently hydrogen, halogen, lower alkyl, lower alkoxy, hydroxy or lower alkanoyloxy, R.sup.4 is lower haloalkyl or lower alkyl, X is sulfur, oxygen or NH, and Y is lower alkylthio, lower alkylsulfonyl or sulfamoyl, which exerts superior anti-inflammatory activity, and highly inhibits COX-2 induced in inflamed sites, with less inhibitory action on COX-1 present in stomach, kidney, etc. Pharmaceutical agents comprising the compound of the present invention are provided as selective COX-2 inhibitors, and anti-inflammatory agents rarely accompanying adverse actions including attacks on gastric mucosa.Type: GrantFiled: October 7, 1999Date of Patent: October 24, 2000Assignee: Grelan Pharmaceutical Co., Ltd.Inventors: Tomoji Aotsuka, Nagatoshi Wagatsuma, Hideo Kato, Naoki Ashizawa
-
Patent number: 5700819Abstract: Unique benzothiazole derivatives which exert superior aldose redactase inhibiting actions are unexpectedly and advantageously useful in the prophylactic and therapeutic treatment of diabetic complications. A benzothiazole derivative compound of the formula (1): ##STR1## wherein X is halogen, R.sup.1 and R.sup.2, which are the same or different, are each independently hydrogen or halogen, A is a methylene group or a sulfur atom, and --B--COOR.sup.3 is a group as defined in the specification; or a pharmaceutically acceptable salt and a pharmaceutical composition comprising the same which is a useful prophylactic or therapeutic agent for the treatment of diabetic complications.Type: GrantFiled: November 22, 1995Date of Patent: December 23, 1997Assignee: Grelan Pharmaceutical Co., Ltd.Inventors: Tomoji Aotsuka, Naoki Abe, Naoki Ashizawa
-
Patent number: 5658924Abstract: The present invention relates to 1,8-naphthyridin-2-one derivatives, pharmaceutically acceptable acid addition salts and therapeutic agents comprising said compound as an active ingredient, which are used for the diseases such as circulatory diseases and respiratory diseases (e.g. hypertension, renal failure, heart failure, angina pectoris, myocardial infarction, arteriosclerosis, romsoongiitis obliterans, aortitis syndrome, bronchial asthma and peripheral diseases such as peripheral circulatory disorders), central nervous system diseases (e.g. depression, degradatior of central nervous function after cerebrovascular obliteration, cerebrovascular dementia, senile dementia, Alzheimer dementia and memory learning function disorders), various inflammations, and obesity.Type: GrantFiled: June 1, 1995Date of Patent: August 19, 1997Assignee: The Green Cross CorporationInventors: Akihiro Matsuura, Naoki Ashizawa, Takema Hase